
Effectiveness and Costs of Osteoporosis Screening and Hormone Replacement Therapy, Vol. I: Cost-Effectiveness Analysis

August 1995

OTA-BP-H-160 GPO stock #052-003-01423-8



Recommended Citation: U.S. Congress, Office of Technology Assessment, Effectiveness and Costs of Osteoporosis Screening and Hormone Replacement Therapy, Volume I:

Cost-Effectiveness Analysis, OTA-BP-H-160 (Washington, DC: U.S. Government

Printing Office, August 1995).

$\mathbf{F}_{\mathbf{oreword}}$

enopause typically occurs in women around age 50. Accompanying this life event is a decline in estrogen levels and an increase in the rate of decline in women's bone density. This rapid bone loss increases women's subsequent risk of developing osteoporosis, a disease characterized by low bone density and increased bone fragility. Among the most serious consequences of osteoporosis is fracture of the hip, which may result in substantial morbidity, prolonged hospitalization, and death. Estrogen can prevent bone loss after menopause by replacing the body's own estrogen. Given the serious consequences of osteoporosis, some osteoporosis experts have recommended that women have their bone mineral density measured at the time of menopause and those with the lowest bone mineral density be offered *hormone replacement therapy*, comprising estrogen given alone or in combination with the hormone progestin.

This background paper, Effectiveness and Costs of Osteoporosis Screening and Hormone Replacement Therapy, assesses the medical benefits and costs of both screening and hormone replacement therapy. It is divided into two volumes. The first volume, Cost-Effectiveness Analysis, presents the results of a model that estimates the cost per year of life gained from osteoporosis screening and hormone replacement therapy in postmenopausal women. The second volume, Evidence on Benefits, Risks, and Costs, provides the basis for the assumptions about the costs and effects of screening and hormonal replacement therapy used in the cost-effectiveness model.

This background paper is one of three documents resulting from OTA's assessment of policy issues in the prevention and treatment of osteoporosis. This assessment was requested by the Senate Special Committee on Aging, Senator Charles Grassley and Senator John Glenn, and the House Select Committee on Aging, Representative Olympia J. Snowe, Representative Benjamin A. Gilman, and former Representatives Brian J. Donnelly, Thomas J. Downey, and Patricia F. Saiki. Two background papers in this series have been issued, both in July 1994: *Public Information about Osteoporosis: What's Available, What's Needed?*, and *Hip Fracture Outcomes in People Age Fifty and Over*.

ROGER C. HERDMAN

Director

Advisory Panel

Robert P. Heaney

John A. Creighton Professor Creighton University Omaha, Nebraska

Steven R. Cummings

Research Director College of Medicine University of California San Francisco, California

Barbara L. Drinkwater

Research Physiologist Pacific Medical Center Seattle, Washington

Deborah T. Gold

Assistant Professor Duke University Medical Center Durham, North Carolina

Susan L. Greenspan

Director Osteoporosis Prevention and Treatment Center Beth Israel Hospital Boston, Massachusetts

Caren Marie Gundberg

Assistant Professor Department of Orthopedics Yale University School of Medicine New Haven, Connecticut

Sylvia Hougland

Dallas, Texas

Conrad C. Johnston

Director
Division of Endocrinology &
Metabolism
Indiana University School of
Medicine
Indianapolis, Indiana

Shiriki K. Kumanyika

Associate Director for Epidemiology Center for Biostatistics & Epidemiology College of Medicine Pennsylvania State University Hershey, Pennsylvania

Edward O. Lanphier, II

Executive Vice President for Commercial Development Somatix Therapy Corporation Alameda, California

Donald R. Lee

Vice President Procter and Gamble Pharmaceuticals Norwich, New York

Robert Lindsay

Chief, Internal Medicine Helen Hayes Hospital West Haverstraw, New York

Betsy Love

Program Manager Center for Metabolic Bone Disorders Providence Medical Center Portland, Oregon

Robert Marcus

Director Aging Study Unit Virginia Medical Center Palo Alto, California

Lee Joseph Melton, III

Head, Section of Clinical
Epidemiology
Department of Health Sciences
Research
Mayo Clinic
Rochester, Minnesota

Gregory D. Miller

Vice President Nutrition Research/Technical Services National Dairy Council Rosemont, Illinois

Morris Notelovitz

President and Medical Director Women's Medical & Diagnostic Center & the Climacteric Clinic, Inc.

Gainesville, Florida

William Arno Peck

Dean Washington University School of Medicine St. Louis, Missouri

Diana B. Petitti

Director, Research and Evaluation Kaiser Permanente Southern California Permanente Medical Group Pasadena, California

Neil M. Resnick

Chief, Geriatrics Brigham and Women's Hospital Boston, Massachusetts

Gideon A. Rodan

Executive Director Department of Bone Biology Merck, Sharp & Dohme Research West Point, Pennsylvania

Mehrsheed Sinaki

Professor, Physical Medicine and Rehabilitation Mayo Medical School Rochester, Minnesota

Milton C. Weinstein

Henry J. Kaiser Professor Health Policy and Management Harvard School of Public Health Boston, Massachusetts

Project Staff

Clyde J. Behney

Assistant Director, OTA

Sean R. Tunis

Health Program Director

ADMINISTRATIVE STAFF

Louise Staley

Office Administrator

Carolyn Martin

Administrative Secretary

Monica Finch

Word Processing Specialist

PRINCIPAL CONTRACTORS

Dennis M. Black

Department of Clinical Epidemiology University of California, San

Francisco

Elliott Pickar

Consultant, Rockville, MD PROJECT STAFF

Robert McDonough Study Director

Judith L. Wagner

Senior Associate

Katie Maslow

Senior Associate

Douglas Teich

Senior Analyst

Laura Stricker

Research Assistant

William Adams

Research Assistant

Julia Bidwell

Research Assistant

Angela Schreiber

Research Assistant